Form PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 038602-1325	SERIAL NO. 10/076,621
INFORMATION DISCLOSURE CITATION	APPLICANT Peng Cho TANG et al.	
(Use several sheets if necessary)	FILING DATE 02/19/2002	GROUP ART UNIT ~~1645~~ 1626

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1	Re 36,256	07/20/1999	Spada et al.			
	A2	2,872,372	02/03/1959	Hull			
	A3	2,968,557	01/17/1961	Burgardt et al.			
	A4	4,002,749	01/11/1977	Rovnyak			
	A5	4,053,613	10/11/1977	Rovnyak et al.			
	A6	4,376,110	03/08/1983	David et al.			
	A7	4,642,309	02/10/1987	Michel et al.			
	A8	4,826,847	05/02/1989	Michel et al.			
	A9	4,853,403	08/01/1989	Shiraishi et al.			
	A10	4,868,304	09/19/1989	Larock et al.			
	A11	4,966,849	10/30/1990	Vallee et al.			
	A12	4,971,996	11/20/1990	Shiraishi et al			
	A13	5,051,417	09/24/1991	Nadler et al.			
	A14	5,057,538	10/15/1991	Shiraishi et al.			
	A15	5,089,516	02/18/1992	Shiraishi et al.			
	A16	5,124,347	06/23/1992	Connor et al.			
	A17	5,202,341	04/13/1993	Shiraishi et al.			
	A18	5,206,261	04/1993	Kawaguchi et al.			
	A19	5,217,999	06/08/1993	Levitzki et al.			
	A20	5,302,606	04/12/1994	Spada et al.			
	A21	5,322,950	06/1994	Sircar et al.			
	A22	5,330,992	07/19/1994	Eissenstat et al.			
	A23	5,374,652	12/20/1994	Buzzetti et al.			
	A24	5,382,593	01/1995	Le Baut			
	A25	5,397,787	03/14/1995	Buzzetti et al.			
	A26	5,409,949	04/1995	Buzzetti et al.			
	A27	5,463,052	10/31/1995	Haga et al.			
	A28	5,786,488	07/28/1998	Tang et al.			
	A29	5,792,783	08/11/1998	Tang			
	A30	5,840,745	11/24/1998	Buzzetti et al.			
	A31	5,849,710	12/15/1998	Battistini et al.			
	A32	5,880,141	03/09/1999	Tang et al			

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 038602-1325	SERIAL NO. 10/076,621
INFORMATION DISCLOSURE CITATION		APPLICANT Peng Cho TANG et al.	
(Use several sheets if necessary)		FILING DATE 02/19/2002	GROUP ART UNIT 1626 ~~1645~~.

	A33	5,883,113	03/16/1999	Tang et al.				
	A34	5,883,116	03/16/1999	Tang et al.				
	A35	5,886,020	03/23/1999	Tang et al.				
	A36	6,130,238	10/2000	Tang et al.				
	A37	6,147,106	11/2000	Tang et al.				

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	TRANSLATION NO
	A38	286870	12/04/1964	AU				
	A39	2,012,634	09/20/1991	CA				
	A40	878539	06/05/1953	DE				
	A41	2,159,360	06/14/1973	DE				
	A42	2,159,361	06/14/1973	DE				
	A43	2,159,362	06/14/1973	DE				
	A44	2,159,363	06/14/1973	DE				
	A45	2,321,656	11/15/1973	DE				
	A46	3,310,891	09/27/1984	DE				
	A47	3,426,419	01/23/1986	DE				
	A48	0 252 713	01/13/1988	EP				
	A49	0 351 213	01/17/1990	EP				
	A50	0 566 226	01/15/1993	EP				
	A51	0 525 472	02/03/1993	EP				
	A52	0 580 502	01/26/1994	EP				
	A53	0 632 102	06/15/1994	EP				
	A54	0 626 377	11/30/1994	EP				
	A55	0 632 102	04/01/1995	EP				
	~~A56~~	~~0 662 473~~	~~07/12/1995~~	EP				
	A57	~~0 788 890~~	~~08/13/1997~~	EP				
	A58	1,398,224	03/29/1965	FR				
	A59	2,689,397	10/08/1993	FR				
	A60	Unknown	10/12/1992	HU				
	A61	62-29570	02/07/1987	JP				
	A62	62-39564	02/20/1987	JP				
	A63	63-141955	06/14/1988	JP				
	A64	558894	03/09/1993	JP				
	A65	92-86777	11/04/1997	JP				

Form PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 038602-1325	SERIAL NO. 10/076,621
INFORMATION DISCLOSURE CITATION	APPLICANT Peng Cho TANG et al.	
(Use several sheets if necessary)	FILING DATE 02/19/2002	GROUP ART UNIT 1626 ~~1645~~

	A66	809691	03/04/1959	UK				
	A67	835473	05/18/1960	UK				
	A68	1,384,599	02/19/1975	UK				
	A69	~~88/07035~~	09/22/1988	WO				
	A70	91/13055	09/05/1991	WO				
	A71	91/15495	10/17/1991	WO				
	A72	92/21660	04/10/1992	WO				
	A73	92/07830	05/14/1992	WO				
	A74	~~92/20642~~	11/26/1992	WO				
	A75	92/21660	12/10/1992	WO				
	A76	93/01182	01/21/1993	WO				
	A77	93/23040	11/25/1993	WO				
	A78	~~94/03427~~	02/17/1994	WO				
	A79	94/10202	05/11/1994	WO				
	A80	94/14808	07/07/1994	WO				
	A81	~~95/01349~~	01/12/1995	WO				
	A82	95/14667	06/01/1995	WO				
	A83	95/17181	06/29/1995	WO				
	~~A84~~	~~95/24190~~	~~09/14/1995~~	WO				
	~~A85~~	~~96/00226~~	~~01/04/1996~~	WO				
	~~A86~~	~~96/16964~~	~~06/06/1996~~	WO				
	A87	96/22976	08/01/1996	WO				
	A88	96/32380	10/17/1996	WO				
	A89	96/40116	12/19/1996	WO				
	A90	97/25986	07/24/1997	WO				
	A91	97/36867	10/09/1997	WO				
	A92	98/07695	02/26/1998	WO				
	A93	98/07835	02/26/1998	WO				
	A94	98/45708	~~10/15/1998~~	WO				
	A95	~~98/50356~~	11/12/1998	WO				
	A96	98/56376	12/17/1998	WO				
	A97	99/10325	03/04/1999	WO				

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

RECEIVED
AUG 09 2002
TECH CENTER 1600/2900

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 038602-1325	SERIAL NO. 10/076,621
		APPLICANT Peng Cho TANG et al.	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		FILING DATE 02/19/2002	GROUP ART UNIT 1626 ~~1645~~

	A98	Abramovitch and Hey, "Internuclear cyclisation. Part VIII. Naphth[3:2:1-cd]oxindoles," J. Chem. Soc. pp. 1697-1703 (1954)
	A99	Abramovitch et al., "A Novel Synthesis of a Cyclic Hydroxamic Acid Involving a Molecular Rearrangement," Chemistry and Industry 44:1871 (1967)
	A100	Abramovitch, Beilstein Reg. No. 236050, J. Chem. Soc., pages 1697, 1700 (1954)
	A101	Akbasak and Suner-Akbasak et al., "Oncogenes: cause or consequence in the development of glial tumors," J. Neurol. Sci. 111:119-133 (1992)
	A102	Andreani et al., "In Vivo Cardiotonic Activity of Pyridylmethylene-2-indolinones," Arzneimittel-Forschung Drug Research 48 (II): 727-729(1998)
SGS	A103	Andreani et al., "Potential antitumor agents. 25[1]. Synthesis and cytotoxic activity of 3-(2-chloro-3-indolylmethlene) 1,3-Dyhydroindol-2-ones," AntiCancer Research 16:3585-3588 (1996)
	A104	Andreani et al., "Synthesis and cardiotonic activity of 2-indolinones," Eur. J. Med. Chem. 25:187-190 (1990)
	A105	Andreani et al., "Synthesis and cardiotonic activity of 2-indolinones," Chemical Abstracts, Vol. 113, abstract no. 78106 (1990)
	A106	Andreani et al., "Synthesis and cardiotonic activity of 2-indolinones bearing pyridyl groups," Eur. J. Med. Chem. 28:653-657 (1993)
	A107	Andreani et al., "Synthesis and cardiotonic activity of pyridylmethylene-2-indolinones," Eur. J. Med. Chem. 27:167-170 (1992)
SGS	A108	Andreani et al., "Synthesis and potential coanthracyclinic activity of substituted 3-(5-imidazo [2, 1-b]thiazolymethylene)-2-indolinones," Eur. J. Med. Chem. 32:919-924 (1997)
	A109	Andreani et al., "Synthesis of lacatams with potential cardiotonic activity," Eur. J. Med. Chem. 28:825-829 (1993)
	A110	Arteaga et al., "Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice," J. Clin. Invest. 84:1418-1423 (1989)
	A111	Arvidsson et al., "Tyr-716 in the Platelet-Derived Growth Factor β-Receptor Kinase Insert is Involved in GRB2 Binding and Ras Activation," Molecular and Cellular Biology 14:6715-6726 (1994)
	A112	Autrey and Tahk, "The Synthesis and Sterochemistry of Some Isatylideneacetic Acid Derivatives," Tetrahedron 23:901-917 (1967)
	A113	Bahner et al., "Benzylideneindenes with Oxygen Attached to the Indene Ring," J. Med. Chem. 12:721-722 (1969)
	A114	Bamfield et al., "Diels-Alder Reactions of Oxindolylideneacetone," J. Chem. Soc. (C) pp. 1028-1030 (1966)
	A115	Baserga, "Oncogenes and the strategy of growth factors," Cell 79:927-930 (1994)
	A116	Baserga, "The insulin-like growth factor I receptor: a key to tumor growth?" Cancer Res. 55:249-252 (1995)
	A117	Beilstein Reg. No. 235647 (1997)
	A118	Beilstein Reg. No. 233511 (1997)

Form PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 038602-1325	SERIAL NO. 10/076,62
INFORMATION DISCLOSURE CITATION	APPLICANT Peng Cho TANG et al.	
(Use several sheets if necessary)	FILING DATE 02/19/2002	GROUP ART UNIT 1626 ~~1645~~

	A119	Beilstein Reg. No.: 252929 (1923)
	A120	Blake and Jaques, "Anistropic Effects in alpha-substituted methoxystilbenes," J. Chem. Soc. Perkin II pp. 1660-1663 (1973)
	A121	Blake and Jaques, "Anistropic Effects in alpha-substituted methoxystilbenes," Chemical Abstracts, Vol. 80, abstract no. 26692 (1974)
	A122	Bolen, "Nonreceptor tyrosine protein kinases," Oncogene 8:2025-2031 (1993)
	A123	Bolen et al., "The Src family of tyrosine protein kinases in hemopoietic signal transduction," FASEB J. 6:3403-3409 (1992)
	A124	Bonner et al., "Structure and Biological Activity of Human Homologs of the *raf/mil* Oncogene," Molecular and Cellular Biology 5:1400-1407 (1986)
	A125	Borsche et al., "Über nielkernige kondersierte systeme mit heterocyclischen ringen," Liebigs Ann. Chem. 550:160-174 (1941)
	A126	Buzzetti et al., "Cinnamamide Analogs as Inhibitors of Protein Tyrosine Kinases," Il Farmaco 48(5):615-636 (1993)
	A127	Cance et al., "Novel Protein Kinases Expressed in Human Breast Cancer," Int J. Cancer 54:571-577 (1993)
	A128	Canoira and Rodriguez, "Synthesis of Oxindole Derivatives from N-Alkenyl-o-Chloroanilides with Zero-Valent Nickel Complex," J. Heterocyclic Chem. 22:1511-1518 (1985)
	A129	Carpenedo et al., "Identification and Measurement of Oxindole (2-Indolinone) in the Mammalian Brain and Other Rat Organs," Analytical Biochemistry 244:74-79 (1997)
	A130	Chao, "Growth Factor Signaling: Where is the Specificity?" Cell 68:995-997 (1992)
	A131	Chatten et al., "Substituted Oxindoles. Part VI. Polarographic Reduction of Substituted trans-3-Benzylideneindol-2(3H)-ones," J. Chem. Soc. Perkin II pp. 469-473 (1973)
	A132	Chen et al., "Effects of 3,3-Dipyridylmethyl-1-Phenyl-2-Indolinone on γ-Aminobutyric Acid Elicited Chloride Current of Snail Central Neuron," Chinese Journal of Physiology 40(3):149-156 (1997)
	A133	Claesso-Welsh, "Signal Transduction by the PDGF Receptors," Progress in Growth Factor Research 5:37-54 (1994)
	A134	Coda et al., "(Z)- and (E)-Arylidene-1,3-dihydroindol-2-ones: Configuration, Conformation and Infrared Carbonyl Stretching Frequencies," J. Chem. Soc. Perkin II pp. 615-619 (1984)
	A135	Coda et al., "(Z)- and (E)-Arylidene-1,3-dihydroindol-2-ones: Configuration, Conformation and Infrared Carbonyl Stretching Frequencies," Chemical Abstracts, Vol. 101, abstract no. 37875 (1984)
	A136	Coda et al., "3-(4-methylbenzilidene)-1-,3-dihydroindol-2-one," J. Chem. Soc. Perkin II, Database Crossfire, Beilstein Ref. No. 6-21, 4: 615-620 (1984)
	A137	Coppola et al., "A Functional Insulin-Like Growth Factor I Receptor is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor," Molecular and Cellular Biology 14:4588-4595 (1994)

Form PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 038602-1325	SERIAL NO. 10/076,621
INFORMATION DISCLOSURE CITATION	APPLICANT Peng Cho TANG et al.	
(Use several sheets if necessary)	FILING DATE 02/19/2002	GROUP ART UNIT 1626 ~~1645~~

	A138	Daisley, "Thin-layer chromatographic separation of some substituted 3-benzylidine-indol-2(3H)-ones," J. Chromatography 100:240-242 (1974)
	A139	Daisley, "Thin-layer chromatographic separation of some substituted 3-benzylidine-indol-2(3H)-ones," Chemical Abstracts Vol. 82, abstract no. 72891 (1975)
	A140	Damiani et al., "Inhibition of Cooper-Mediated Low Density Lipoprotein Peroxidation by Quinoline and Indolinone Nitroxide Radicals," Biochemical Pharmacology 48(6):1155-1161 (1994)
	A141	Dati et al., "Inhibition of *c-erb*B-2 oncogene expression by estrogens in human breast cancer cells," Oncogene 5:1001-1006 (1990)
	A142	Davis et al., "Synthesis and Microbiological Properties of 3-Amino-1-Hydroxy-2-Indolinone and Related Compounds," Journal of Medicinal Chemistry 16(9):1043-1045 (1973)
	A143	Decker and Lohmann-Matthes, "A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity," J. Immunol. Methods 15:61-69 (1988)
	A144	De Vries et al., "The *fms*-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," Science 255:989-991 (1992)
	A145	Dickson et al., "Tyrosine kinase receptor-nuclear protooncogene interactions in breast cancer," Cancer Treatment Res. 61:249-273 (1992)
	A146	Elliot, "1-methyl-2-(3-oxindolidenmethyl)-pyridinium," Database Crossfire, Beilstein Ref. No. 5-24, March 19, 1991, XP 002049951
	A147	Elliott and Rivers, "Reduction of some oxindolylidene derivatives to 3-substituted oxindoles by sodium borohydride," J. Organic Chem. 29:2438-2440 (1964)
	A148	Fantl et al., "Distinct Phosphotyrosines on a Growth Factor Receptor Bind to Specific Molecules That Mediate Different Signaling Pathways," Cell 69:413-423 (1992)
	A149	Fendly et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human or Epidermal Growth Factor Receptor or HER2/*neu* Gene Product" Cancer Research 50:1550-1558 (1990)
	A150	Ferrara and Henzel, "Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells," Biochemical and Biophysical Research Communications 161:851-858 (1989)
	A151	Fingl and Woodbury, Chapter 1, pp. 1-46 in The Pharmacological Basis of Therapeutic (5th edition), eds. Goodman et al., MacMillan Publishing Co., Inc., New York (1975)
	A152	Floege et al., "Factors involved in the regulation of mesangial cell proliferation *in vitro in vivo*," Kidney International 43S:47-54 (1993)
	A153	Floege et al., "Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis," Kidney International 43:369-380 (1993)
	A154	Folkman and Shing, "Angiogenesis," J. Biol. Chem. 267:10931-10934 (1992)
	A155	~~Folkman, "What is the Evidence that Tumors are Angiogenesis Dependent?" Journal of the National Cancer Institute 82:4-6 (1990)~~

Form PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 038602-1325	SERIAL NO. 10/076,621
INFORMATION DISCLOSURE CITATION	APPLICANT Peng Cho TANG et al.	
(Use several sheets if necessary)	FILING DATE 02/19/2002	GROUP ART UNIT 1626 ~~1645~~

	A156	Folkman, "Ch. 24. Angiogenesis, "Congress of Thrombosis and Haemostasis (Verstraete et al., eds.) Leuven University Press, Leuven pp. 583-596 (1987)
	A157	Folkman, "Tumor Angiogenesis: Therapeutic Implications" New England J. Medicine 285:1182-1186 (1971)
	A158	Gazit et al., "Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2-neu tyrosine-kinases," J. Med. Chem. 34(6):1896-1907 (1991)
	A159	Gennaro (editor), Remington's Pharmaceutical Sciences (1990)(TABLE OF CONTENTS ONLY)
	A160	Goldring and Goldring, "Cytokines and cell growth control," Critical Reviews in Eukaryotic Gene Expression 1:301-326 (1991)
	A161	Gottardis et al., "Estradiol-Stimulated Growth of MCF-7 Tumors Implanted in Athymic Mice: A Model to Study the Tumoristatic Action of Tamoxifen," J. Steroid Biochem. 30(1-6):311-314 (1988)
	A162	Graziani et al., "Hepatocyte Growth Factor/Scatter Factor Stimulates the Ras-Guanine Nucleotide Exchanger," The Journal of Biological Chemistry 268(13):9165-9168 (1993)
	A163	Hewgill and Stewart, "Phenanthrene-4,5-quinones: a Synthesis of Morphenol," J.Chem. Soc. Perkin Trans. I pp. 1305-1311 (1988)
	A164	Hodges et al., "Chemical and biological properties of some oxindolidyl-3-methines," Canadian J. Chemistry 46:2189-2194 (1968)
	A165	Honegger et al., "Point Mutation at the ATP Binding Site of EGF Receptor Abolishes Protein-Tyrosine Kinase Activity and Alters Cellular Routing," Cell 5:199-209 (1987)
	A166	Houben-Weyl., "Substance Index," Cyclic Compounds V Bicyclic Compounds 1 E231:834-1018 (1999)
	A167	Houck et al., "Dual Regulation of Vascular Endothelial Growth Factor Bioavailability Genetic and Proteolytic Mechanisms," J. Biol. Chem. 267:26031-26037 (1992)
	A168	Howard et al., Provisional Patent Application No. 60/015,134 filed March 29, 1996 for "Lactam Derivatives"
	A169	Howard et al., "Synthesis and aldose reductase inhibitory activity of substituted 2(1*H*)-benzimidazolone- and oxindole-1-acetic acids," Eur. J. Med. Chem. 27:779-789 (1992)
	A170	Howard et al., "Synthesis and aldose reductase inhibitory activity of substituted 2(1*H*)-benzimidazolone- and oxindole-1 acetic acids" Chemical Abstracts, Vol. 118, abstract no. 254813 (1993)
	A171	Hu et al., "Interaction of Phosphatidylinositol 3-Kinase-Associated p85 with Epidermal Growth Factor and Platelet-Derived Growth Factor Receptors," Molecular and Cellular Biology 12(3):981-990 (1992)
	A172	Ijaz et al., "The Conversion of o,β-Dinitrostyrenes into Indoles and the Preparation of Oxindole Quinones," J. Chem. Res. (S) pp. 116 (1990)
	A173	Ijaz et al., "The Conversion of o,β-Dinitrostyrenes into Indoles and the Preparation of Oxindole Quinones," Chemical Abstracts, Vol. 113, abstract no. 93739 (1990)
	A174	Jellinek et al., "Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor," Biochemistry 33:10450-10456 (1994)
	A175	Kashishian and Cooper, "Phosphorylation Sites at the C-terminus of the Platelet-Derived Growth Factor Receptor Bind Phospholipase Cγ1," Molecular Biology of the Cell 4:49-57 (1993)

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 038602-1325	SERIAL NO. 10/076,621
INFORMATION DISCLOSURE CITATION		APPLICANT Peng Cho TANG et al.	
(Use several sheets if necessary)		FILING DATE 02/19/2002	GROUP ART UNIT 1626 ~~1645~~

	A176	Kashishian et al., "Phosphorylation Sites in the PDGF receptor with Different Specificities for Binding GAP and P13 Kinase *in vivo*," The EMBO Journal 11(4):1373-1382 (1992)
	A177	Kato et al., "Simultaneous Determination of Amfenac Sodium and its Metabolite (7-Benzoyl-2-Oxindole) in Human Plasma by High-Performance Liquid Chromatography," Journal of Chromatography 616:67-71 (1993).
	A178	Katritzky et al., "Color and Constitution. Part 8[1]. Some Novel Dyestuffs Containing Indoxyl Residues," J. Heterocyclic Chem. 25:1287-1292 (1988)
	A179	Kazlauskas et al., "The 64-kDa Protein That Associates with the Platelet-Derived Growth Factor Receptor β Subunit via Tyr-1009 Is The SH2-Containing Phosphotyrosine Phosphatase Syp," Proc. Natl. Acad. Sci. USA 90:6939-6942 (1993)
	A180	Kendall and Thomas, "Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor," Proc. Natl. Acad. Sci. USA 90:10705-10709 (1993)
	A181	Khalil and Abdel-Rahman, "Synthesis of New Mero- and Asymmetrical Pyrazolo-Monomethine Cyanine Dyes," J. Indian Chem. Soc., 54:904-907 (1977)
	A182	Kim et al., "Inhibition of Vascular endothelial growth factor-induced angiogenesis suppresses tumor growth *in vivo*," Nature 362:841-844 (1993)
	A183	Kinsella et al., "Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel," Exp. Cell Research 199:52-62 (1992)
	A184	Klagsburn and Soker, "VEGF/VPF: the angiogenesis factor found?" Current Biology 3:699-702 (1993)
	A185	Kobayashi et al., "Anti-tumor Activity of Indole Derivatives," Yakugaku Zasshi 97(9):1033-1039 (1977)
	A186	Koch et al., "SH2 and SH3 Domains: Elements that Control Interactions of Cytoplasmic Signalling Proteins," Science 252:668-674 (1991)
	A187	Köhler and Milstein, "Continuous cultures of fused cells secreting antibody of predefined specificity," Nature 256:495-497 (1975)
	A188	Komada et al., "The cell dissociation and motility triggered by scatter factor/hepatocyte growth factor are mediated through the cytoplasmic domain of the c-Met receptor," Oncogene 8:2381-2390 (1993)
	A189	Korc et al., "Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha," J. Clin. Invest. 90:1352-1360 (1992)
	A190	Korzeniewski and Callewaert, "An Enzyme-Release Assay for Natural Cytotoxicity[1]," J. Immunol. Methods 64:313-320 (1983)
	A191	Kovac and Stetinova, "Furan derivatives LXXX. Synthesis and properties of substituted furfurylidenoxindoles," Chem. rvesu 30:484-492 (1976)
	A192	Krueger and Saito, "A human transmembrane protein-tyrosine-phosphatase, PTP, is expressed in brain and has an N-terminal receptor domain homologous to carbonic anhydrases," Proc. Natl. Acad. Sci. USA 89:7417-7421 (1992)
	A193	Kumbae et al., "Amplificiation of α-platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin," Oncogene 7:627-633 (1992)

Form PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 038602-1325	SERIAL NO. 10/076,621
INFORMATION DISCLOSURE CITATION	APPLICANT Peng Cho TANG et al.	
(Use several sheets if necessary)	FILING DATE 02/19/2002	GROUP ART UNIT 1626 ~~1645~~

	A194	Larock and Babu, "Synthesis of Nitrogen Heterocycles via Palladium-catalyzed Intramolecular Cyclization," Tetrahedron Letters 28:52991-52994 (1987)
	A195	Lee and Donoghue, "Intracellular retention of membrane-anchored v-*sis* protein abrogates autocrine signal transduction," Journal of Cell Biology 118:1057-1070 (1992)
	A196	Levitzki and Gazit, "Tyrosine kinase inhibition: An approach to drug development," Science 267:1782-1788 (1995)
	A197	Maas et al., "Viral resistance to the thiazolo-iso-indolinoes, a new class of nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase," Antimicrobial Agents and Chemotherapy 37(12):2612-2617 (1993)
	A198	Macauley et al., "Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells," Cancer Research 50:2511-2517 (1990)
	A199	Mariani et al., "Inhibition of angiogenesis by FCE 26806, a potent tyrosine kinase inhibitor," Experimental Therapeutics – Proceedings of the American Association for Cancer Research 35:381 at abstract no. 2268 (1994)
	A200	Martín-Leòn et al., "On the Cyclization to the Elusive Amino-*4H*-pyran Ring," Liebigs Ann. Chem. pp. 101-104 (1990)
	A201	Millauer et al., "High Affinity VEGF Binding and Developmental Expression Suggest Flk-1 as a Major Regulator of Vasculorgenesis and Angiogenesis," Cell 72:885-846 (1993)
	A202	Mirand et al., "A Synthetic Entry in the *Aristotelia* Alkaloids," J. Org. Chem. 47:4169-4170 (1982)
	A203	Mohammad et al., "Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors," Science 276:955-960 (1997)
	A204	Moreto et al., "3,3-Bis-(4-Hydroxyphenyl)-7-Methyl-2-Indolinone (BHMI), the Active Metabolite of the Laxative Sulisatin," Arzneimittel-Forschung Drug Research 29(II):1561-1564 (1979)
	A205	Moreto et al., "Study of the Laxative Properties of the Disodium Salt of the Sulfuric Diester of 3,3 Bis-(4-Hydroxyphenyl)-7-Methyl-2-Indolinone (Dan-603) in the Rat," European Journal of Pharmacology 36:221-226 (1976)
	A206	Morrison et al., "Signal transduction from membrane to cytoplasm: Growth factors and membrane-bound oncogene products increase Raf-1 phosphorylation and associated protein kinase activity," Proc. Natl. Acad. Sci. USA 85:8855-8859 (1988)
	A207	Mosmann, "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays," J. Immunol. Methods 65:55-63 (1983)
	A208	Neber and Rocker, "Ueber die einwirkung vbon benzaldehyden auf die freie o-aminophenyl-essigsaure," Chem. Ber. 56:1710-1717 (1923) (with translation)
	A209	Nishimura et al., "Two Signaling Molecules Share a phosphotyrosine-Containing Binding Site in the Platelet-Derived Growth Factor Receptor," Molecular and Cellular Biology 13:6889-6896 (1993)
	A210	Nodiff et al., "Antimalarial Phenanthrene Amino Alcohols. 1. Fluorine-Containing 3- and 6-Substituted 9-Phenanthrenemethanols," Chemical Abstracts, Vol. 765, abstract no. 21121 (1972)

Form PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 038602-1325	SERIAL NO. 10/076,621
INFORMATION DISCLOSURE CITATION	APPLICANT Peng Cho TANG et al.	
(Use several sheets if necessary)	FILING DATE 02/19/2002	GROUP ART UNIT 1626 ~~1645~~

	A211	Nodiff et al., "Antimalarial Phenanthrene Amino Alcohols. 3. Halogen-containing 9-phenanthrenemethanols," Chemical Abstracts, Vol. 83, abstract no. 188214 (1975)
	A212	Nodiff et al., "Antimalarial Phenanthrene Amino Alcohols. 1. Fluorine-Containing 3- and 6-Substituted 9-Phenanthrenemethanols," J. Med. Chem. 14:921-925 (1971)
	A213	O'Sullivan and Rothery, "The Preparation and Possible Clinical Significance of 4'-Dialkylaminoisoindogenides," Clinica Chimica Acta 62:181-182 (1975)
	A214	Osborne et al., "Effect of Estrogens and Antiestrogens on Growth of Human Breast Cancer Cells in Athymic Nude Mice," Cancer Research 45:584-590 (1985)
	A215	Ozzello and Sordat, "Behavior of Tumors Produced by Transplantation of Human Mammary Cell Lines in Athymic Nude Mice," Eur. J. Cancer 16:553-559 (1980)
	A216	Pavlenko et al., "Introduction of aminomethyl groups into heterocyclic CH-acid molecules," Dopov. Akad. Nauk Ukr. RSR 7:64-66 (1980)
	A217	Plate, "Vascular endothelial growth factor is potential tumor angiogenesis factor in human gilomas *in vivo*," Nature 359:845-848 (1992)
	A218	Plowman et al., "Receptor Tyrosine Kinases as Targets for Drug Intervention," DN&P 7(6):334-339 (1994)
	A219	Quinn et al., "Fetal Liver Kinase 1 is a Receptor for Vascular Endothelial Growth Factor and is Selectively Expressed in Vascular Endothelium," Proc. Natl. Acad. Sci. USA 90:7533-7537 (1993)
	A220	Rozakis-Adcock et al., "Association of the Shc and Grb2-Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases," Nature 360:689-692 (1992)
	A221	Ruveda and Gonzalez, "Geometric isomerism in benzylideneoxindoles," Spectrochimica Acta 26A:1275-1277 (1970)
	A222	Rygaard and Povlsen, "Heterotransplantation of a Human Malignant Tumour to 'Nude' Mice," Acta path. microbiol. scand. 77:758-760 (1969)
	A223	Saito and Streuli, "Molecular Characterization of Protein Tyrosine Phosphatases," Cell Growth & Differentation 2:59-65 (1991)
	A224	Sandberg-Nordqvist et al., "Characterization of insulin-like growth factor 1 in human primary brain tumors," Cancer Res. 53:2475-2478 (1993)
	A225	Schindler et al., "Dibenz[*b,f*]-azocin-Derivate," Helvetica Chimica Acta 49:985-989 (1966)
	A226	Schlessinger and Ullrich, "Growth Factor Signalling by Receptor Tyrosine Kinases," Neuron 9:383-391 (1992)
	A227	Schnierle et al., "Vilsmeier-Reaktion mit Pyrrol- und Pyrrolon-Derivaten," Liebigs Ann. Chem. 715:90-97 (1968)
	A228	Schuchter et al., "Successful Treatment of Murine Melanoma With Bryostatin 1," Cancer Research 51:682-687 (1991)
	A229	Seibert et al., "Clonal Variation of MCF-7 Breast Cancer Cells *in Vitro* and in Athymic Nude Mice," Cancer Research 43:2223-2239 (1983)
	A230	Shafie and Grantham, "Role of Hormones in Growth and Regression of Human Breast Cancer Cells (MCF-7) Transplanted into Athymic Nude Mice," J. Natl Cancer Institute 67(1):51-56 (1981)

Form PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 038602-1325	SERIAL NO. 10/076,621
INFORMATION DISCLOSURE CITATION	APPLICANT Peng Cho TANG et al.	
(Use several sheets if necessary)	FILING DATE 02/19/2002	GROUP ART UNIT 1626 ~~1645~~

	A231	Shibuya et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (*flt*) closely related to the *fms* family," Oncogene 5:519-524 (1990)
	A232	Shiraishi et al., "Specific Inhibitors of Tyrosine-specific Protein Kinases: Properties of 4-Hydroxycinnamamide Derivatives in Vitro," Cancer Research 49:2374-2378 (1989)
	A233	Shiraishi, "Specific inhibitors of Tyrosine-Specific Protein Kinase, Synthetic 4- Hydroxycinnamamide Derivatives," Biochemical and Biophysical Research Communications 147:322-328 (1987)
	A234	Shweiki et al., "Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis," Nature 359:843-845 (1992)
	A235	Singh et al., "Indolinone Derivatives as Potential Antimicrobial Agents," Zentralbl. Mikrobiol. 144:105-109 (1989)
	A236	Singh et al., "Synthesis and Anticonvulsant Activity of New 1-Substituted 1'-Methyl-3-Chloro-2-Oxosprio (Azetidin-3', 4-Indol-2' Ones)," Bollettino Chimico Farmaceutico 133:76-79 (1994)
	A237	Skehan et al., "New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening," J. Natl. Cancer Inst. 82:1107-1112 (1990)
	A238	Slamon et al., "Studies of the HER/2-*neu* Proto-oncogene in Human Breast and Ovarian Cancer," Science 244:707-712 (1989)
	A239	Soldi et al., "Platelet-Activating Factor (PAF) Induces the Early Tyrosine Phosphorylation of Focal Adhesion Kinase ($p125^{FAK}$) in Human Endothelial Cells," Oncogene 13(3):515-525 (1996)
	A240	Songyang et al., "SH2 Domains Recognize Specific Phosphopeptide Sequences," Cell 72:767-778 (1993)
	A241	Songyang et al., Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk and Vav," Molecular and Cellular Biology 14:2777-2785 (1994)
	A242	Spada and Myers, "Small molecule inhibitors of tyrosine kinase activity," Expert Opinion on Therapeutic Patents 5(8):805-817 (1995)
	A243	Stetinova et al., "Stereochemistry and Photoisomerisation of Furfurylideneoxindoles," Collection Czecholslov. Chem. Commun. 42:2201-2206 (1976)
	A244	Stolle, Beilstein Reg. No. 273650, J. Prakt. Chem., Vol. 2, page 128 (1930)
	A245	Sumpter and Miller, "Chapter IV – Oxindole," in Heterocyclic Compounds With Indole and Carbazole Systems, Interscience Publishers, Inc., New York, pp. 134-153 (1954)
	A246	Sun et al., "Synthesis and biological evaluations of 3-substituted indolin-2-ones: A novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases," J. Med. Chem. 41:2588-2603 (1998)
	A247	Superti-Furga et al., "A functional screen in yeast for regulators and antagonizers of heterologous protein tyrosine kinases," Nature Biotech 14:600-605 (1996)
	A248	Superti-Furga et al., "Csk inhibition of c-Src activity requires both the SH2 and SH3 domains of Src," EMBO J. 12:2625-2634 (1993)
	A249	Tacconi and Marinone, "Preparazione e caratteristiche di alcuni 3-ossindolidenderivati," Ricerca Scientifica 38:1239-1244 (1968)

Form PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 038602-1325	SERIAL NO. 10/076,621
INFORMATION DISCLOSURE CITATION	APPLICANT Peng Cho TANG et al.	
(Use several sheets if necessary)	FILING DATE 02/19/2002	GROUP ART UNIT 1626 ~~1645~~

	A250	Tacconi et al., "(Z)- and (E)-3-Alkylidene-1,3-dihydroindol-2-ones: Influence of Configuration on the Transmission of the Inductive Effect to the Carbonyl Group," J.C.S. Perkin II pp. 150-154 (1976)
	A251	Takano et al., "Inhibition of angiogenesis by a novel diaminoanthraquinone that inhibits protein kinase C," Mol. Bio. Cell 4:358A (1993), at abstract no. 2076
✓	A252	Terrett et al., "Combinatorial synthesis- the design of compound libraries and their application to drug discovery," Tetrahedron 51(30):8135-8173 (1995)
	A253	Thompson et al., "Facile Dimerisation of 3-Benzylideneindoline-2-thiones," J. Chem. Soc. Perkin Trans. (I) pp. 1835-1837 (1993)
	A254	Torp et al., "Expression of the epidermal growth factor receptor gene in human brain metastases," AMPIS 100:713-719 (1992)
	A255	Traxler, "Protein tyrosine kinase inhibitors in cancer treatment," Expert Opinion on Therapeutic Patents 7(6):571-588 (1997)
	A256	Treibs et al., "Uber isoindigoide Farbstroffe der Pyrrol-Reihe," Liebigs Ann. Chem. 702:112-130 (1967)
	A257	Trost et al. (ed.), "Comprehensive Organic Synthesis," Selectivity, Strategy & Efficiency in Modern Organic Chemistry 4:478 (1991)
	A258	Tsai et al., "The Effect of 3,3-Di-Pyridyl-Methyl-1-Phenyl-2-Indolinone on the Nerve Terminal Currents of Mouse Skeletal Muscles," Neuropharmacology 31(9):943-947 (1992)
	A259	Tuzi et al., "Expression of growth factor receptors in human brain tumours," Br. J. Cancer 63:227-233 (1991)
	A260	Twamley-Stein et al., "The Src Family Tyrosine Kinases are Required for Platelet-Derived Growth Factor-Mediated Signal Transduction in NIH-3T3 Cells," Proc. Natl. Acad. Sci. 90:7696-7700 (1993)
	A261	Ullrich and Schlessinger, "Signal Transduction by Receptors with Tyrosine Kinase Activity," Cell 61:203-212 (1990)
	A262	Vaisman et al., "Characterization of the Receptors for Vascular Endothelial Growth Factor," J. Biol. Chem. 265:19461-19466 (1990)
	A263	Varma and Gupta, "Nucleophilic Reactions of 2-Methyl-3-(4'-carbomethoxyphenyl)-4-quinazolinones with 2-Indolinones," J. Indian Chem. Soc. 66:804-805 (1989)
	A264	Voller et al., "Enzyme-Linked Immunosorbent Assay," in Manual of Clinical Immunology," 2nd edition, Rose and Friedman editors, American Society of Microbiology, Washington D.C., pp. 359-371 (1980)
	A265	von Dobeneck et al., "α.β'-Diindolylmethane und-methene. Der Urorosein-Chromophor," Zur Chemie des Indols VI:1347-1357 (1969)
	A266	Wahl et al., "Chimie Organique - Sur les iso-indogenides," C.R. Hebd. Seancest Acad. Sci. 149:132-134 (July 1909)
	A267	Wahl, "3-benzilidene-5-methyl-1,3-dihydroindol-2-one," Ann. Chim., Database Crossfire, Beilstein Ref. No. 2-21-00-00290, p. 350 (1926)
	A268	Wahl, Beilstein Reg. No. 191439, Bull. Soc. Chim. Fr., page 1038 (1909)
	A269	Wahl, Beilstein Reg. No. 231732, Bull. Soc. Chim. Fr., pages 1035-1038 (1909)

Form PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 038602-1325	SERIAL NO. 10/076,621
INFORMATION DISCLOSURE CITATION	APPLICANT Peng Cho TANG et al.	
(Use several sheets if necessary)	FILING DATE 02/19/2002	GROUP ART UNIT 1626 ~~1645~~

	A270	Walker, "The Reduction of Insoindogenides, Nitro Compounds, and Pyridines in a Series of 2-Indolinones," J. Med. Chem. 8(5):626-637 (1965)
	A271	Walker, "Synthesis of a α-(p-Aminophenyl)- and α-(p-Chlorophenyl)-β-aryl-propionitriles by Catalytic Reduction of Stilbenenitriles," J. Med. Chem. 8(5):583-588 (1965)
	A272	Walker, "Synthesis of New 3-(Pyridylmethylene)-, 3-(Pyridylmethyl)-, 3-(Piperidylmethyl)- and 3-(β-Alkylaminoethyl)-2-indolinones. The Reduction of Isoindogenides, Nitro Compounds, and Pyridines in a Series of 2-Indolinones," J. Med. Chem. 8(5):626-637 (1965)
	A273	Warri et al., "Estrogen Suppression of *erb*B2 Expression is Associated with Increased Growth Rate of ZR-75-I Human Breast Cancer Cells *In Vitro* and in Nude Mice," Int. J. Cancer 49:616-623 (1991)
	A274	Weidner et al., "Tumor Angiogenesis and Metastasis -- Correlation in Invasive Breast Carcinoma," New England J. Medicine 324:1-7 (1991)
	A275	Winkelmann et al., "Chemotherapeutically Active Nitro Compounds: 4. 5-Nitroimidazoles (Part I)," Arzneim.-Forsch /Drug Res. 27(II) 2251-2263 (1977)
	A276	Wright et al., "Cyclic Hydroxamic Acids Derived from Indole," J. Amer. Chem. Soc. 78:221-224 (1956)
	A277	Wright et al., "Inhibition of Angiogenesis in Vitro and In Ovo With an Inhibitor of Cellular Protein Kinases, MDL 27032," J. Cellular Physiology 152:448-457 (1992)
	A278	Wright, Beilstein Reg. No. 244658, J. Amer. Chem. Soc. 78:221-224 (1956)
	A279	Wright, Beilstein Reg. No. 235900, J. Amer. Chem. Soc. 78:221-224 (1956)
	A280	Young and Babbitt, "2-(2-Methyl-3-indolyl)-1,4-benzoquinone, A Reversible Redox Substrate at the Carbon Paste Electrode in Acidic Aqueous-Ethanolic Media," J. Org. Chem. 47:1571-1572 (1982)
	A281	Zaman et al., "Tyrosine Kinase Activity of Purified Recombinant Cytoplasmic Domain of Platelet-Derived Growth Factor β-Receptor (β-PDGFR) and Discovery of a Novel Inhibitor of Receptor Tyrosine Kinases," Biochemical Pharmacology 57(1):57-64 (1999)
	A282	Zhang et al., "Microtubule Effects of Welwistatin, a Cyanobacterial Indolinone that Circumvents Multiple Drug Resistance," Molecular Pharmacology 49:288-294 (1996)
	A283	Zhungietu et al., "Reaction of Indoles and 2-Ketoindolines With Some Aldehydes," Institute of Chemistry, Academy of Science of the Moldavian SSR, Kishinev pp. 34-37 translated from Khimiya Geterotsiklicheskikh Soedinenii 1:40-44 (1973)
	A284	Zhungietu et al., "Reaction of Indoles and 2-Ketoindolines With Some Aldehydes," Chemical Abstracts, Vol. 78, abstract no. 111201 (1973)

EXAMINER	DATE CONSIDERED
Susan J. Stuckin	5/2/03

* **EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.**